메르켈세포암: 국가별 치료 선택지

임상시험 진행 중

• Immune checkpoint inhibitors including avelumab (Bavencio), pembrolizumab (Keytruda), retifanlimab-dlwr (Zynyz); surgery; radiation therapy; chemotherapy; palliative surgery/radiation임상시험임상시험InvestigationalUnited States · Merkel cell polyomavirus (MCPyV) and PD-L1 status discussed by NCI as biologic/evidence context; no biomarker required in fetched FDA approval notices; Advanced MCC first-line systemic context; recurrent locally advanced or metastatic MCC; metastatic MCC; neoadjuvant/adjuvant immunotherapy under clinical evaluation. · NCI PDQ is an evidence summary, not a payer source. FDA accelerated approvals may depend on ongoing confirmatory evidence. This finding does not establish individual eligibility, toxicity suitability, or sequencing among checkpoint inhibitors. Confidence/conflicts: High for U.S. evidence-summary and approvals; accelerated-approval and payer details remain caveats. DailyMed / U.S. FDA label — official drug label
• Pembrolizumab; avelumab; AZD6750; rilvegostomig; INCB099280임상시험 · NCT07302347임상시험Trial only (registry)Japan · MSI-H/dMMR and PD-L1 amplification apply to selected broad solid-tumor cohorts; no MCC biomarker requirement stated for Japan pembrolizumab or avelumab records; Japanese adult MCC; metastatic MCC in JAVELIN Merkel 200; advanced/metastatic solid tumors including MCC. · Registry records do not establish PMDA approval, reimbursement, routine access, or individual eligibility. Broad solid-tumor studies do not prove MCC-specific enrollment at every Japan site. Some studies are completed or active only in specific cohorts. Confidence/conflicts: High for Japan registry-listed MCC-related studies; local approval/access unverified. ClinicalTrials.gov — clinical-trial registry
• Navtemadlin (KRT-232) with or without anti-PD-1/anti-PD-L1 therapy including avelumab; AZD6750 plus rilvegostomig; MDNA11 plus pembrolizumab임상시험 · NCT03787602임상시험Trial only (registry)Korea · MSI-H, dMMR, or high tumor mutational burden may apply to some broad IL-2 study cohorts; no MCC-specific biomarker requirement stated in KRT-232/avelumab record; MCC; advanced or metastatic solid tumors including MCC; advanced/unresectable solid tumor cohorts including MCC. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some study statuses are unknown or active-not-recruiting at South Korea sites. Confidence/conflicts: High for Korea registry-listed MCC activity; regulator/access status unverified. ClinicalTrials.gov — clinical-trial registry
• Cosibelimab (CK-301)임상시험 · NCT03212404임상시험Trial only (registry)Thailand · No biomarker requirement stated in fetched cosibelimab record for MCC cohort; Advanced cancers including Merkel cell carcinoma. · This is a broad advanced-cancer phase 1 record and does not establish MCC-specific enrollment at each Thailand or Russia site. It does not establish Thai FDA or Russian regulator approval, reimbursement, routine access, or current enrollment. Confidence/conflicts: Medium-high for Thailand/Russia broad advanced-cancer registry activity including MCC; MCC-specific site enrollment and local access unverified. ClinicalTrials.gov — clinical-trial registry